A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Clinical trial NCT03989414 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03989414
- Sponsor
- Celgene
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-09-30
- Primary completion
- 2026-11-30
- Enrollment
- 424
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.